USP and Public Policy

usp public policy
Left
usp public policy

Refine Your Search

All Results
USP Comment Letter: Submitted to WHO on INN Biological Qualifier (BQ) Proposal (2014)
USP letter provided support to the efforts of WHO’s INN expert group to develop a consensus-based global approach to the naming of all biologicals that is consistent with existing, accepted… Learn More
USP Comment Letter: Submitted to WHO on Hand Sanitizers (2021)
USP Statement to the WHO on the quality of hand sanitizers, or handrubs, as related to public health emergencies: preparedness and response.  Learn More
USP Statement for the Record: Submitted to the Senate Finance Committee for the Hearing: “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a Federal Health Program Perspective” (2023)
United States Pharmacopeia (USP) Statement for the Record Submitted to the Senate Finance Committee for the Hearing: “Drug Shortages: Examining Supply Challenges, Impacts, and Policy Solutions from a… Learn More
USP Statement for the Record: Submitted to Ways and Means Hearing on Examining Chronic Drug Shortages in the United States (2024)
United States Pharmacopeia (USP) Statement for the Record, submitted to the House Committee on Ways and Means Hearing on Examining Chronic Drug Shortages in the United States. Submitted 2/12/2024. Learn More
USP Statement for the Record: For the Hearing Drug Shortage Health and National Security Risks- Underlying Causes and Needed Reforms (2023)
United States Pharmacopeia (USP) is pleased to submit the following statement for the record on the hearing “Drug Shortage Health and National Security Risks: Underlying Causes and Needed Reforms Learn More
USP White Paper: Principles for a robust and trusted pharmacopeia
The United States Pharmacopeia (USP) has been an independent standards-setting organization serving public health needs since it was founded in 1820. Over the two centuries that followed, USP evolved… Learn More
USP Global Public Policy Position: Recognizing Challenges and Opportunities to Support Adoption of Advanced Manufacturing Technologies for Medical Products
USP Global Public Policy Position on advanced manufacturing technologies (AMTs) for medical products. Published in 2024. Learn More
USP White Paper: Addressing Barriers to the Development of Complex Generics: Understanding Challenges and Opportunities
USP White Paper on addressing Barriers to the Development of Complex Generics. Learn More
USP White Paper: Advancing Regulatory and Pharmacopeial Convergence, Harmonization, and Global Cooperation to Improve Medicines Supply Chain Resiliency
The U.S. Pharmacopeia (USP) recognizes that global coordination, harmonization, and convergence efforts among governments and other stakeholders can facilitate and streamline responses and solutions… Learn More
USP Comments to FDA on the FDA Food Safety Modernization Act -Focus on Inspections and Compliance (2011)
USP comments to FDA on “FDA Food Safety Modernization Act: Focus on Inspections and Compliance” Docket No. FDA-2011-N-0366. Comments were submitted in 2011.  Learn More

Document Classification

Topics